{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:03:38Z","timestamp":1781921018513,"version":"3.54.5"},"reference-count":0,"publisher":"International Institute of Anticancer Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CDP"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:p>Background\/Aim:\nWidespread use of BCR::ABL1 tyrosine kinase inhibitors (TKIs) has transformed the clinical landscape of chronic myeloid leukemia (CML). However, BCR::ABL1 mutation-driven treatment resistance challenges optimal care and outcomes. The purpose of this study was to ascertain real-world practices concerning such mutational profiling in US hematology and oncology practices, which were mainly community-based.\nMaterials and Methods:\nThis is the first chart review of BCR::ABL1 kinase domain mutational profiling in the US. In this study of the Cardinal Health Oncology Provider Extended Network (OPEN), 13 hematologists and\/or oncologists selected charts of adults with chronic-phase CML for approximately equal numbers of patients who underwent such testing (Cohort 1; n=26) or did not (Cohort 2; n=25).\nResults:\nAcross most time points, failure and warning signs by molecular testing were not significantly more frequent in patients who did or did not undergo BCR::ABL1 mutational profiling. Conversely, similar frequencies of optimal milestones were observed in patients with or without testing. Patients who underwent BCR::ABL1 mutational profiling were more likely to have splenomegaly (p=0.0069) versus those who did not.\nConclusion:\nThere were few significant differences in failure and warning signs by molecular testing in patients who did or did not undergo mutational profiling. Patients who underwent BCR::ABL1 mutational profiling were significantly more likely to have splenomegaly, which is not included in consensus guidelines as a reason to conduct such testing. Taken together, these findings raise potential concerns about consensus guideline adherence as a means to optimize CML management for TKI resistance.<\/jats:p>","DOI":"10.21873\/cdp.10518","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T12:32:08Z","timestamp":1772886728000},"page":"186-198","source":"Crossref","is-referenced-by-count":1,"title":["BCR::ABL1 Mutational Profiling in US Patients With Chronic-phase Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitors"],"prefix":"10.21873","volume":"6","author":[{"given":"FADI G.","family":"HADDAD","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ELIAS J.","family":"JABBOUR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"STEPHEN W.","family":"GUTKIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ASHUTOSH K.","family":"PATHAK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YIFAN","family":"ZHAI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HAGOP M.","family":"KANTARJIAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"9336","published-online":{"date-parts":[[2026,3,1]]},"container-title":["Cancer Diagnosis &amp; Prognosis"],"original-title":[],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T12:32:08Z","timestamp":1772886728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cancerdiagnosisprognosis.org\/article\/580\/bcrabl1-mutational-profiling-in-us-patients-with-chronic-phase-chronic-myeloid-leukemia-on-tyrosine-kinase-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,1]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.21873\/cdp.10518","relation":{},"ISSN":["2732-7787"],"issn-type":[{"value":"2732-7787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}